Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients

Phase 2 Completed 90 enrolled University of Michigan Rogel Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine if metformin administered in combination with chemotherapy to women with advanced ovarian, primary peritoneal or fallopian tube cancer will improve recurrence-free survival at 18 months compared to controls.

Timeline

Start: 2011-10
Primary completion: 2017-06
Completion: 2017-07

Outcome

Met primary endpoint

paper Tumors treated with metformin had a 2.4-fold decrease in ALDH+CD133+ CSCs PMID 32369446 ↗

paper relapse-free survival at 18 months of 59.3% (95% CI 38.6-70.5). PMID 32369446 ↗

Publications

Brown JR, Chan DK, Shank JJ, Griffith KA, Fan H, Szulawski R, Yang K, Reynolds RK, Johnston C, McLean K, Uppal S, Liu JR, Cabrera L, Taylor SE, Orr BC, Modugno F, Mehta P, Bregenzer M, Mehta G, Shen H, Coffman LG, Buckanovich RJ. Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight. 2020 Jun 4;5(11):e133247. doi: 10.1172/jci.insight.133247.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metformin	Small molecule	—	—